Case Report 1
Mr A is a 35 year-old man suffering from BD I diagnosed according to DSM-IV criteria (5) , as well as from methamphetamine abuse. His most recent episode was depressed, and he presented in remission. He was taking bupropion sustained release (SR) 150 mg twice daily and divalproex 750 mg twice daily. Mr A complained that, since restarting divalproex 1 month prior to consultation, he was sleeping 12 to 14 hours daily and unable to work. Laboratory examination showed a divalproex level of 85 µg/mL. His complete blood count, hepatic enzymes, serum electrolytes, lipase, amylase, and ammonia were all within normal limits, and a urine drug screen was negative for illicit substances. Mr A denied the use of alcohol and was enrolled in an outpatient rehabilitative program; however, he was not as active as he wanted to be, owing to excessive sedation. To diminish the excessive sedation, he agreed to a reduced divalproex dosage, and this medication was decreased from 750 mg twice daily to 500 mg twice daily. A serum divalproex level was maintained in the therapeutic range at 67 µg/mL. Unfortunately, he continued to experience daytime somnolence. He agreed to a trial of modafinil initiated at 100 mg daily. He did not experience any side effects and noted decreased sedation within 1 week of starting modafinil. After 1 week of modafinil at 100 mg, his dosage was increased to 200 mg daily, with marked improvement. He was sleeping 8 hours nightly and felt awake during the day. He was able to participate in family life and was able to find employment after having been unemployed for 9 months and at one time thinking of filing for permanent disability. His divalproex levels have remained within the therapeutic range while he is on modafinil. He remains stable at 1 year, with no triggering of hypomanic or manic symptoms associated with modafinil.
Case Report 2
Mr B is a 27-year-old man diagnosed with BD I and obsessive-compulsive disorder (OCD) according to DSM-IV criteria (5) . His most recent episode was manic. He was taking divalproex 500 mg every morning and 750 mg at bedtime, sertraline 200 mg daily, quetiapine fumarate 75 mg at bedtime, and clonazepam 1 mg daily. He had recently been hospitalized but had been compliant for 2 months on the medications. He complained of sleeping 14 hours daily. His serum level of divalproex was 87 µg/mL. The rest of his laboratory examination included a complete blood couont, hepatic panel, pancreatic enzymes, ammonia, serum electrolytes, and urine drug screen, all of which were unremarkable. The clonazepam and quetiapine were tapered off to determine to what extent they might have contributed to Mr B's sedation. After discontinuing the clonazepam and quetiapine, he slept about 12 hours nightly. The divalproex was decreased by 250 mg at night with no decrease in next-day sedation. Mr B agreed to a trial of modafinil started at 200 mg daily. He experienced a mild anxious feeling. Within 1 week, his daytime sedation was markedly improved, and he was averaging 7 to 8 hours of sleep nightly. He remains stable at 1 year with no noted exacerbation of mood symptoms or worsening of his OCD. As well, while on modafinil, his subsequent divalproex serum levels have been therapeutic.
Modafinil is approved in the by the US Food and Drug Administration to treat excessive daytime somnolence associated with narcolepsy. It is chemically unrelated to the psychostimulants (6) . It is thought to alter the balance of GABA and glutamate, resulting in activation of the hypothalamus (7, 8) . Modafinil has been used as an adjunct in the treatment of major depression, allowing patients to achieve remission as well as targeting residual tiredness (9) . Makela and others recently reported the successful use of modafinil to treat sedation induced by antipsychotics in 3 patients (10). Although I reduced my patients' medication and tapered concomitant medications that could have contributed to sedation, I felt that modafinil could alleviate their excessive sedation. Because it is structurally unrelated to traditional stimulants, I did not expect to trigger hypomania or mania. In Mr A's case, I considered the possibility of substance abuse, although modafinil does not appear to have abuse potential (11) . Modafinil also did not appear to alter serum levels of divalproex, which is another important consideration.
To my knowledge, this is the first report of using modafinil to treat excessive sedation associated with divalproex sodium. Case reports must be interepreted with caution; however, modafinil may be useful in treating excessive sedation associated with divalproex sodium. Further studies in a controlled manner are encouraged.
Ziprasidone in Parkinson's Disease Psychosis
Dear Editor:
Hallucinations and delusions are frequent side effects of dopaminergic treatment in Parkinson's disease (PD) patients. These patients do not generally tolerate typical antipsychotic therapy with D 2 antagonist drugs. Ziprasidone is a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. Clinical trials suggest that the drug is effective in treating schizophrenia (1) . We report remission of psychosis and improvement of motor symptoms in a PD patient taking ziprasidone.
Case Report
Mr A, a 70-year-old man with a 16-year history of PD, was admitted to our department for levodopa-induced psychosis. Antipsychotic treatment with clozapine had been effective but had to be discontinued owing to agranulocytosis. At admission, the patient was treated with L -DOPA/carbidopa 1200 mg, L -DOPA/benserazide 375 mg, entacapone 1200 mg, and quetiapine 800 mg daily. He had pronounced visual, auditory, and tactile hallucinations, as well as delusions of persecution. Physical examination showed hypomimia, stooped posture, and a slight resting tremor of the right hand. There were infrequent (< 1 daily) off-episodes, with akinesia and rigidity lasting up to 1.5 hours. Otherwise, activities of daily life were only moderately affected. The Uniform Parkinson Disease Rating Scale (UPDRS) score was 43/199. The results of laboratory tests and the findings on cranial magnetic resonance imaging, ECG, and EEG were unremarkable. L-DOPA/benserazide and quetiapine were discontinued without apparent effect. Aripiprazole 10 mg thrice daily was tried but revealed no benefit and had to be discontinued after 4 weeks, owing to motor side effects. At discontinuation, the UPDRS score was 101. Ziprasidone was initiated at 40 mg once daily and increased to 80 mg once daily over 3 days. Within 2 weeks, delusions and hallucinations subsided, and motor function improved fundamentally. Sitting, walking, dressing, showering, and eating without assistance became possible. On discharge, the UPDRS score was 42.
Ziprasidone is one of the newer atypical antipsychotic drugs; these drugs tend to cause fewer extrapyramidal side effects (EPSEs) than classic neuroleptics. Within the group, atypical neuroleptics have varying propensities to cause EPSEs. Clozapine appears to be superior in this regard and is widely recognized as a standard treatment for dopaminergic psychosis in PD. Experience with ziprasidone is lacking, and EPSE frequency has been estimated to equate that of olanzapine, which is not well tolerated in PD (2) . In our opinion, however, the choice of a neuroleptic drug in PD should depend on the probability of drug-induced Parkinson's symptoms and not of drug-induced dystonia, hyperkinesia, akathisia, and myoclonus-all of which are EPSEs. Two substances with the same overall EPSE frequency may not be equally safe in patients with PD. Akathisia has been reported with ziprasidone (3), and we have also encountered acute dystonia. However, Parkinson's symptoms occur rarely if at all, and therefore, ziprasidone may become a real alternative treatment for PD psychosis.
Combined Oral Venlafaxine and Intravenous Clomipramine-A: Successful Temporary Response in a Patient With Extremely Refractory Depression
We report a case of a married woman, aged 33 years, with treatment-refractory dependent and borderline personality disorder and major depression with atypical features, diagnosed according to DSM-IV criteria. She began to experience free-floating anxiety and incomplete panic attacks at age 26 years, which were soon followed by major depression. Two years later, at age 28 years, she presented to our outpatient clinic. She had already attempted suicide once by swallowing pills a couple of months prior to presenting. Her psychiatric family history was blank.
Given 1 mg dexamethasone, she was a nonsuppressor on the dexamethasone suppression test (DST) (based on the cut-off point of 5 µg/dL plasma cortisol) and had blunted response to 30 mg dexfenfluramine challenge test (cut-off 50 µU/L prolactin). Brain-imaging single photon emission computed tomography (SPECT) showed increased regional cerebral blood flow in the frontal lobes (+1.5 sd) and reduced regional cerebral
